Strategy of Daiichi Sankyo discovery research in oncology.
We would like to introduce Daiichi Sankyo's approach to developing cancer targeted medicines with special reference to the drug discovery strategy, global discovery activities and external research collaboration leading to generation of innovative drugs for cancer patients. We are developing 14 clinical projects for cancer treatment and three of them have been previously approved. These are mostly targeted for growth and survival signals of cancer cells. To overcome the drug resistance mechanism derived from the heterogeneous nature of cancer, we are developing selective inhibitors in three major clusters of signal pathways which may allow future rational combinations of oncology products. In addition to the main research facility in Japan, research sites in the EU and the USA provide us with different technical expertise and diversified ideas of drug discovery. To access novel drug targets, we are facilitating research collaboration with leading academia and successful cancer research scientists. In conclusion, we intend to focus more on developing innovative personalized medicines for better treatment of cancer.
*Shinagawa R&D Center, Daiichi Sankyo Co., Ltd, 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. akahane.koichi.c8@daiichisankyo.co.jp.
Kouichi
K
Akahane
Kazunori
K
Hirokawa
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D055808:Drug Discovery / Q000639:trends; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005062:European Union; D006801:Humans; D007391:International Cooperation; D007564:Japan; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D057285:Precision Medicine / Q000639:trends; D015398:Signal Transduction / Q000187:drug effects*; D014481:United States
D000970:Antineoplastic Agents
Daiichi Sankyo; drug discovery; targeted medicine